↑ 薬物リストへ　← 戻る

Gm-csf [leukine (sargramostim)]    (DrugBank: Sargramostim)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
229肺胞蛋白症（自己免疫性又は先天性）1

229. 肺胞蛋白症（自己免疫性又は先天性）　［臨床試験数：35，薬物数：30（DrugBank：8），標的遺伝子数：3，標的パスウェイ数：12］
Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 35 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00901511
(ClinicalTrials.gov)		July 200911/5/2009Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar ProteinosisPulmonary Alveolar ProteinosisDrug: GM-CSF [Leukine (Sargramostim)];Procedure: WLLIRCCS Policlinico S. MatteoAgenzia Italiana del FarmacoEnrolling by invitation18 YearsN/ABoth18Phase 2;Phase 3Italy